Jonathan Mow
Director Ejecutivo en PHASEBIO PHARMACEUTICALS, INC. .
Cargos activos de Jonathan Mow
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/09/2014 | - |
| Director Ejecutivo | 01/09/2014 | - | |
| Corporate Officer/Principal | 04/12/2012 | 01/09/2014 | |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Director Ejecutivo | 20/06/2023 | - |
Historial de carrera de Jonathan Mow
Antiguos cargos conocidos de Jonathan Mow.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2007 | - |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Fundador | 01/01/2001 | 01/01/2006 |
| Secretario Corporativo | 01/01/2001 | 01/01/2006 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1995 | 01/01/1997 |
| Syntex Laboratories, Inc. | Corporate Officer/Principal | - | - |
| Lederle International | Corporate Officer/Principal | - | - |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Corporate Officer/Principal | - | - |
Formación de Jonathan Mow.
| University of California, Berkeley | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 11 |
Operativa
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectorial
| Health Technology | 7 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
PathoGenesis Corp
PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
| Lederle International | |
| Syntex Laboratories, Inc. | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Jonathan Mow
- Experiencia
